Kimialys
Cyril Gilbert is the CEO of Kimialys, a company that develops and sells surface chemistry for nanoparticles and biochips to enhance the performance of diagnostic tests. Prior to this, Cyril worked as an Investment Analyst at Jolt Capital, focusing on growth capital investments in deep-tech companies. Cyril also has experience as a Junior Analyst at Turenne Capital and co-founded Gustave, a luggage transfer service in Paris. Cyril has a Master's Degree from HEC Paris and an Engineer's Degree from Institut d'Optique Graduate School.
This person is not in any teams
Kimialys
We are a team of chemists and biosensor engineers gathered around a common mission: shaping the future of biodetection for a better world. Kimialys is the result of 10 years of meticulous academic research in surface chemistry. Controlling what is happening on the surface is a fundamental aspect of biosensing techniques such as rapid tests, point-of-care diagnostics, and real-time sensors. Without the right surface interactions, even the most advanced biosensors can falter, leading to misleading results. Our research efforts have always been to optimize these crucial parameters, ensuring both precision and reliable biodetection. Founded in 2020, Kimialys is leading the charge in harnessing surface chemistry to revolutionize diagnostics and drug development, all supported by our patented K-One® technology. Building on this foundation, our coated gold nanoparticles elevate rapid diagnostic tests in terms of sensitivity, specificity and reproducibility. Additionally, our expertise in sensor chip functionalisation combined with our expertise in Surface Plasmon Resonance analysis empowers us to detect, screen, and select the most suitable biologics for both diagnostic and therapeutic applications. Reliability, robustness, and adaptability are not just benefits of our technology; they are the cornerstones of the relationships we build. For every customer we collaborate with, thousands of patients stand to benefit from our work.